In Europe, Science Corporation has commercially launched PRIMA, a retinal implant designed to restore central vision in people with geographic atrophy (GA). The treatment has been shown in clinical trials to restore functional central vision in people with GA who until now had no way to get lost central vision back. While PRIMA is available in Europe, it is still going through FDA approvals in the U.S. Geographic atrophy is an advanced form of age-related macular degeneration (AMD) that leads to progressive vision loss. AMD is the most common cause of blindness in individuals over the age of 55 in developed countries.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Foundation Fighting Blindness. Innehållet i podden är skapat av Foundation Fighting Blindness och inte av, eller tillsammans med, Poddtoppen.